TABLE 4.
Duration (Min) | ||||||||
---|---|---|---|---|---|---|---|---|
Acute Drug | Chronic Treatment | Sex | Minute Ventilation | Tidal Volume | Frequency | Peak Inspiratory Flow | Inspiratory Time | Apneic Pause |
Heroin | Fentanyl | Female | 10a | 5a | 15a,b | 20a | 20b,c | NA |
Male | 0 | 0 | 0 | 20a | 40b | NA | ||
Saline | Female | 25a | 5a | 20a,b | 35a | 45c | 20c | |
Male | 10a | 5a | NA | 30a | 50c | NA | ||
Fentanyl | Fentanyl | Female | 0 | 5a | 10a | 10a | 15c | 5b,c |
Male | 0 | 0 | 5a,b | 10a | 15c | 10c | ||
Saline | Female | 10a | 0 | 15a | 15a | 15c | 15c | |
Male | 5a | 5a | 5a,b | 10a | 15c | 10c |
NA, not applicable.
Post hoc comparisons following one-way ANOVA separated by sex and dose.
aP < 0.05, decreased from baseline (direction of respiratory depression for minute ventilation, tidal volume, frequency, and peak inspiratory flow).
bLate onset.
cP < 0.05, increased from baseline (direction of respiratory depression for inspiratory time and apneic pause).